项目动态 ｜ 超4亿美元！祐森健恒与阿斯利康就KRAS G12D抑制剂达成全球独家授权协议
今日（2023年11月 20 日 ）， 分享投资被投企业「祐森健恒生物医药（上海）有限公司（以下简称“祐森健恒”）」宣布已与阿斯利康(LSE/STO/Nasdaq: AZN)就临床前阶段的靶向KRASG12D突变的小分子候选药物UA022项目达成全球独家授权协议。
根据协议条款，阿斯利康将获得UA022的研究、开发和商业化的全球独家授权许可。祐森健恒将有资格获得 2400万美元的首付款，此外还将获得最高达3.95亿美元的潜在开发和商业化里程碑付款，以及净销售额的分级特许权使用费。
祐森健恒联合创始人、CEO胡滔博士表示：“KRASG12D是癌症中最普遍的KRAS突变，但目前还没有获批的针对KRASG12D的治疗方案。我们很高兴与全球领先的生物制药公司阿斯利康达成这项协议，来评估UA022的治疗潜力。UA022的发现和验证是多方合作与努力的结果，我们对包括药明康德在内的诸多合作伙伴的支持表示感谢。”
阿斯利康副总裁、肿瘤研发部门开发负责人Stephen Fawell表示:“基于阿斯利康在靶向肿瘤驱动因子和突变方面的传统，此次与祐森健恒达成许可协议是一个令人振奋的机会，可以加速开发针对肿瘤携带KRASG12D突变患者的潜在新疗法，这是一个未满足医疗需求的领域。”
关于UA022
UA022是一种有效的、选择性靶向KRASG12D突变的口服小分子药物。KRAS突变在多种癌症类型中发生率很高，其中G12D最为常见，约占所有KRAS突变的26%[1]。它普遍存在于胰腺癌、结直肠癌、非小细胞肺癌等。目前还没有批准的KRASG12D抑制剂，这些患者需要新的治疗选择。UA022已显示出强大的抗癌活性，具有良好的安全性，并且在临床前模型中展示出良好的口服生物利用度。
关于祐森建恒
祐森健恒成立于2020年1月，聚焦于癌症和自身免疫疾病两大领域，围绕新靶点、新作用机制开发具有全球自主知识产权的创新药。目前，公司已有多个癌症相关和自身免疫疾病药物进入临床。
参考资料：
[1] Hofmann MH, et al. (2022) Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. DOI: 10.1158/2159-8290.CD-21-1331
Usynova Announces Global Exclusive License Agreement with AstraZeneca for UA022, a Novel KRASG12D-Targeting Small Molecule Drug Candidate
Shanghai, China, November 20, 2023 - Usynova Pharmaceuticals Ltd. ("Usynova") announced today that it has entered into a global exclusive license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for UA022, a pre-clinical stage small molecule drug candidate targeting the KRASG12D mutation.
Under the terms of the agreement, AstraZeneca will be granted a global exclusive license to research, develop and commercialize UA022. Usynova will be eligible to receive an upfront payment of $24 million, and additional development and commercial milestone payments of up to $395 million, as well as tiered royalties.
Dr. Tao Hu, Co-founder and CEO of Usynova, said, "There are currently no approved treatments targeting KRASG12D, which is the most prevalent of KRAS mutations in cancer. We are pleased to enter into this agreement with AstraZeneca, a leading biopharmaceutical company, to investigate the therapeutic potential of UA022. The discovery and validation of this asset has been a truly collaborative effort and we express gratitude to our partners including WuXi AppTec for their support."
Stephen Fawell, Vice President, Discovery Oncology R&D, AstraZeneca said, “Building on AstraZeneca’s legacy in targeting tumour drivers and mutations, this license agreement with Usynova is an exciting opportunity to accelerate the development of a potential new treatment for patients whose tumours harbour KRASG12D mutations, an area of unmet medical need.”
About UA022
UA022 is a potent and selective, oral small molecule drug targeting the KRASG12D mutation. KRAS mutations occur at a high frequency across multiple cancer types, with G12D being the most common, constituting approximately 26% of all KRAS mutations [1]. It is prevalent in pancreatic cancer, colorectal cancer, non-small cell lung cancer, amongst others. There are currently no approved KRASG12D inhibitors, and new treatment options are required for these patients. UA022 has demonstrated robust anti-cancer activity, a promising safety profile, and encouraging oral bioavailability across preclinical models.
About Usynova
Founded in January 2020, Usynova focuses on two major areas, cancer and autoimmune diseases, and develops innovative medicines with global intellectual property rights based on new targets and new mechanisms of action. The company has some cancer-related and autoimmune disease drugs into the clinic stage.
reference：
[1] Hofmann MH, et al. (2022) Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants. Cancer Discov. DOI: 10.1158/2159-8290.CD-21-1331
资料来源：祐森健恒